Aliskiren Hemifumarate; Valsartan Patent Expiration
Aliskiren Hemifumarate; Valsartan is Used for managing high blood pressure. It was first introduced by Novartis Pharmaceuticals Corp
Aliskiren Hemifumarate; Valsartan Patents
Given below is the list of patents protecting Aliskiren Hemifumarate; Valsartan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Valturna | US8168616 | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension | Jul 03, 2026 | Novartis |
| Valturna | US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul 21, 2018
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Aliskiren Hemifumarate; Valsartan's patents.
Latest Legal Activities on Aliskiren Hemifumarate; Valsartan's Patents
Given below is the list recent legal activities going on the following patents of Aliskiren Hemifumarate; Valsartan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 03 Jun, 2024 | US8168616 |
| Maintenance Fee Reminder Mailed Critical | 18 Dec, 2023 | US8168616 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Oct, 2019 | US8168616 |
| Post Issue Communication - Certificate of Correction | 23 Jul, 2013 | US8168616 |
| Patent Issue Date Used in PTA Calculation Critical | 01 May, 2012 | US8168616 |
| Recordation of Patent Grant Mailed Critical | 01 May, 2012 | US8168616 |
| Email Notification Critical | 12 Apr, 2012 | US8168616 |
| Issue Notification Mailed Critical | 11 Apr, 2012 | US8168616 |
| Dispatch to FDC | 04 Apr, 2012 | US8168616 |
| Application Is Considered Ready for Issue Critical | 29 Mar, 2012 | US8168616 |
Aliskiren Hemifumarate; Valsartan's Family Patents
